P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).
Paul G. Richardson,Asher A. Chanan-Khan,Robert L. Schlossman,Nikhil C. Munshi,Patrick Y. Wen,Hannah Briemberg,David J. Kuter,Anne Louise Oaklander,Sagar Lonial,Hani Hassoun,Deborah Doss,Kathleen Colson,Mary McKenney,Karen Hande,Alexandra Koryzna,Barbara Stoklas,Laura E. Lunde,Svetlana Gorelik,Cliona McAlister,Andrea Freeman,Diane Warren,Denise Collins,Dixie Lee Esseltine,Anthony A. Amato,Kenneth C. Anderson +24 more
TL;DR: Single agent bortezomib is a promising approach for newly diagnosed pts and is without the complications of high-dose dex, and the incidence of subclinical PN by NCS at baseline prior to therapy is currently 30.
Journal ArticleDOI
Emerging therapies for multiple myeloma.
TL;DR: The scientific rationale of new therapy regimens and newly identified therapeutic agents – small molecules as well as therapeutic antibodies – that hold promise to further improve outcome in multiple myeloma are reviewed.
Journal ArticleDOI
Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research
Christopher Strouse,Paul G. Richardson,Grant Prentice,Sandra Korman,Robin Hume,Bijan Nejadnik,Mary M. Horowitz,Wael Saber +7 more
TL;DR: The results of this study are consistent with previously reported experiences with defibrotide, confirm the poor outcome of this syndrome, and suggest defib rotide is effective in the treatment of severe VOD.
Journal ArticleDOI
Complete genome sequence of the filamentous gliding predatory bacterium Herpetosiphon aurantiacus type strain (114-95T)
Hajnalka Kiss,Hajnalka Kiss,Markus Nett,Nicole Domin,Karin Martin,Julia A. Maresca,Alex Copeland,Alla Lapidus,Susan Lucas,Kerrie W. Berry,Tijana Glavina del Rio,Eileen Dalin,Hope Tice,Sam Pitluck,Paul G. Richardson,David Bruce,David Bruce,Lynne Goodwin,Lynne Goodwin,Cliff Han,Cliff Han,John C. Detter,John C. Detter,Jeremy Schmutz,Thomas Brettin,Thomas Brettin,Miriam Land,Miriam Land,Loren Hauser,Loren Hauser,Nikos C. Kyrpides,Natalia Ivanova,Markus Göker,Tanja Woyke,Hans-Peter Klenk,Donald A. Bryant +35 more
TL;DR: The genome of H. aurantiacus strain 114-95T is the first completely sequenced genome of a member of the family Herpetosiphonaceae, and is of interest not only because of its rather isolated position in the tree of life, but also because HerpetOSiphon ssp.
Journal ArticleDOI
Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
Douglas W. McMillin,Hannah M. Jacobs,Jake Delmore,Leutz Buon,Zachary R. Hunter,Val Monrose,Jie Yu,Peter G. Smith,Paul G. Richardson,Kenneth C. Anderson,Steven P. Treon,Andrew L. Kung,Constantine S. Mitsiades +12 more
TL;DR: The NEDD8-activating enzyme is upstream of the 20S proteasome in the ubiquitin/proteasome pathway and catalyzes the first step in the neddylation pathway and provides the framework for the clinical investigation of MLN4924 in multiple myeloma.